Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG).
Por:
Dittner-Moormann S, Reschke M, Abbink FCH, Aerts I, Atalay HT, Fedorovna Bobrova N, Biewald E, Brecht IB, Caspi S, Cassoux N, Castela G, Diarra Y, Duncan C, Ebinger M, Garcia Aldana D, Hadjistilianou D, Kepák T, Klett A, Kiratli H, Maka E, Opocher E, Pawinska-Wasikowska K, Rascon J, Russo I, Rutynowska-Pronicka O, Sábado Álvarez C, Pacheco SSR, Svojgr K, Timmermann B, Vishnevskia-Dai V, Eggert A, Ritter-Sovinz P, Bechrakis NE, Jenkinson H, Moll A, Munier FL, Popovic MB, Chantada G, Doz F and Ketteler P
Publicada:
1 jun 2021
Ahead of Print:
15 mar 2021
Resumen:
INTRODUCTION: Advanced intraocular retinoblastoma can be cured by enucleation, but spread of retinoblastoma cells beyond the natural limits of the eye is related to a high mortality. Adjuvant therapy after enucleation has been shown to prevent metastasis in children with risk factors for extraocular retinoblastoma. However, histological criteria and adjuvant treatment regimens vary and there is no unifying consensus on the optimal choice of treatment. METHOD: Data on guidelines for adjuvant treatment in European retinoblastoma referral centres were collected in an online survey among all members of the European Retinoblastoma Group (EURbG) network. Extended information was gathered via personal email communication. RESULTS: Data were collected from 26 centres in 17 countries. Guidelines for adjuvant treatment were in place at 92.3% of retinoblastoma centres. There was a consensus on indication for and intensity of adjuvant treatment among more than 80% of all centres. The majority of centres use no adjuvant treatment for isolated focal choroidal invasion or prelaminar optic nerve invasion. Patients with massive choroidal invasion or postlaminar optic nerve invasion receive adjuvant chemotherapy, while microscopic invasion of the resection margin of the optic nerve or extension through the sclera are treated with combined chemo- and radiotherapy. CONCLUSION: Indications and adjuvant treatment regimens in European retinoblastoma referral centres are similar but not uniform. Further biomarkers in addition to histopathological risk factors could improve treatment stratification. The high consensus in European centres is an excellent foundation for a common European study with prospective validation of new biomarkers.
Filiaciones:
Dittner-Moormann S:
Department of Pediatric Hematology and Oncology, University Duisburg-Essen, University Hospital Essen, Essen, Germany
Reschke M:
Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany
Abbink FCH:
Amsterdam UMC, Location VU University Medical Centre, Amsterdam, The Netherlands
Aerts I:
Institut Curie, PSL Research University and University of Paris, Paris, France
Atalay HT:
Gazi University School of Medicine, Ankara, Turkey
Fedorovna Bobrova N:
Filatov Eye Institute Odessa, Odessa, Ukraine
Biewald E:
Department of Ophthalmology, University Duisburg-Essen, University Hospital Essen, Essen, Germany
Brecht IB:
Children's Hospital, University of Tuebingen, Tuebingen, Germany
Caspi S:
Pediatric Oncology, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel
Cassoux N:
Institut Curie, PSL Research University and University of Paris, Paris, France
Castela G:
Centro Hospitalar e Universitário de Coimbra, University of Coimbra, Coimbra, Portugal
Diarra Y:
Department of Pediatric Hematology and Oncology, University Duisburg-Essen, University Hospital Essen, Essen, Germany
Duncan C:
Royal London Hospital and Great Ormond Street Hospital, London, England
Ebinger M:
Children's Hospital, University of Tuebingen, Tuebingen, Germany
Garcia Aldana D:
Hospital Virgen Macarena, Sevilla, Spain
Hadjistilianou D:
Ocular Oncology, Siena University Hospital, Siena, Italy
Kepák T:
University Hospital Brno and St. Anna University Hospital/ICRC, Masaryk University, Brno, Czech Republic
Klett A:
East-Tallinn Central Hospital, Tallinn, Estonia
Kiratli H:
Hacettepe University Hospital, Ankara, Turkey
Maka E:
Department of Ophthalmology, Semmelweis University, Budapest, Hungary
Opocher E:
Royal London Hospital and Great Ormond Street Hospital, London, England
Pediatric Hematology, Oncology and Stem Cell Transplant Division, Padua University Hospital, Padua, Italy
Pawinska-Wasikowska K:
Department of Pediatric Oncology and Hematology, University Children's Hospital of Krakow, Krakow, Poland
Rascon J:
Centre for Pediatric Oncology and Hematology, Vilnius University, Vilnius, Lithuania
Russo I:
Department of Pediatric Hematology/Oncology, IRCCS, Ospedale Pediatrico Bambino Gesù, Rome, Italy
Rutynowska-Pronicka O:
The Children's Memorial Health Institute, Warsaw, Poland
Sábado Álvarez C:
Pediatric Hematology and Oncology, University Hospital Vall d'Hebron, Barcelona, Spain
Pacheco SSR:
Hospital La Paz, Madrid, Spain
Svojgr K:
Charles University in Prague, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
Timmermann B:
Department of Particle Therapy, University Hospital Essen, West German Proton Therapy Centre Essen (WPE), West German Cancer Center (WTZ), Essen, Germany
German Consortium for Translational Cancer Research (DKTK), Essen, Germany German Cancer Research Center (DKFZ), Heidelberg, Germany
Vishnevskia-Dai V:
The Goldschleger eye institute, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel
Eggert A:
Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany
Ritter-Sovinz P:
Division of Pediatric Hematology/Oncology, Medical University of Graz, Graz, Austria
Bechrakis NE:
Department of Ophthalmology, University Duisburg-Essen, University Hospital Essen, Essen, Germany
Jenkinson H:
Birmingham Children's Hospital, Birmingham, England
Moll A:
Department of Ophthalmology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands
Munier FL:
Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, University of Lausanne, Lausanne, Switzerland
Popovic MB:
Department of Pediatric Hematology and Oncology, University Hospital CHUV, University of Lausanne, Lausanne, Switzerland
Chantada G:
Hospital Sant Joan de Déu, Barcelona, Spain
Doz F:
Institut Curie, PSL Research University and University of Paris, Paris, France
Ketteler P:
Department of Pediatric Hematology and Oncology, University Duisburg-Essen, University Hospital Essen, Essen, Germany
German Consortium for Translational Cancer Research (DKTK), Essen, Germany German Cancer Research Center (DKFZ), Heidelberg, Germany
hybrid, Green Submitted
|